Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis

Authors

  • Leonora de Boo Division of Urology, Department of Surgical Oncology,University Health Network, Toronto, Ontario, Canada and Erasmus MC-beurs, Erasmus University Rotterdam, Netherland
  • Melania Pintilie Clinical Study Coordination and Biostatistics, University Health Network, Toronto, Ontario, Canada
  • Paul Yip Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada
  • Jack Baniel Division of Urology, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Neil Fleshner Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, Ontario, Canada
  • David Margel Division of Urology and Davidoff cancer center, Rabin Medical Center, Beilinson hospital

DOI:

https://doi.org/10.5489/cuaj.2147

Keywords:

radical prostatectomy, prostatic neoplasms, prostate-specific antigen, biochemical recurrence

Abstract

Introduction: In this study, we estimated the time from first detectable prostate-specific antigen (PSA) following radical prostatectomy(RP) to commonly used definitions of biochemical recurrence (BCR). We also identified the predictors of time to BCR.

Methods: We identified subjects who underwent a RP and had an undetectable PSA after surgery followed by at least 1 detectable PSA between 2000 and 2011. The primary outcome was time to BCR (PSA ≥0.2 and successive PSA ≥0.2) and prediction of the rate of PSA rise. Outcomes were calculated using a competing risk analysis, with univariable and multivariable Fine and Grey models. We employed a mixed effect model to test clinical predictors that are associated with the rate of PSA rise.

Results: The cohort included 376 patients. The median follow-up from surgery was 60.5 months (interquartile range [IQR] 40.8–91.5) and from detectable PSA was 18 months (IQR 11–32). Only 45.74% (n = 172) had PSA values ≥0.2 ng/mL, while 15.16% (n = 57) reached the PSA level of ≥0.4 ng/mL and rising. On multivariable analysis, the values of the first detectable PSA and pathologic Gleason grade 8 or higher were consistently independent predictors of time to BCR. In the mixed effect model rate, the PSA rise was associated with time from surgery to first detectable PSA, Gleason score, and prostate volume. The main limitation of this study is the large proportion of patients that received treatment without reaching BCR. It is plausible that shorter estimated median times would occur at a centre that does not use salvage therapy at such an early state.

Conclusion: The time from first detectable PSA to BCR may be lengthy. Our analyses of the predictors of the rate of PSA rise can help determine a personalized approach for patients with a detectable PSA after surgery.

 

Downloads

Download data is not yet available.

Downloads

Published

2015-01-12

How to Cite

de Boo, L., Pintilie, M., Yip, P., Baniel, J., Fleshner, N., & Margel, D. (2015). Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis. Canadian Urological Association Journal, 9(1-2), E14–21. https://doi.org/10.5489/cuaj.2147

Issue

Vol. 9 No. 1-2 (2015): CUAJ January

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.